SCHEMBL26418208

SCHEMBL26418208

CC(C)C(=O)NCc1cc(F)c(OC(=O)C(C)C)c(F)c1

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ERCC1 P07992 1/20 0.47
ERCC4 Q92889 1/20 0.47
CARM1 Q86X55 2/20 0.41
PRMT6 Q96LA8 2/20 0.41
SMO Q99835 1/20 0.39
HPGD P15428 1/20 0.37
S1PR3 Q99500 1/20 0.36
KMT2A Q03164 1/20 0.36
ALOX15 P16050 1/20 0.36
TSHR P16473 1/20 0.36
ADRB2 P07550 1/20 0.36
ADRA2A P08913 1/20 0.36
DRD2 P14416 1/20 0.36
ADRA2C P18825 1/20 0.36
DRD1 P21728 1/20 0.36
ADRA1A P35348 1/20 0.36
DRD3 P35462 1/20 0.36
PTGES O14684 3/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23417836 0.88 ERCC1 (0.47) ERCC1ERCC4CARM1PRMT6SMO
SCHEMBL26428853 0.87 HPGD (0.39) CARM1PRMT6HPGDS1PR3
SCHEMBL26422825 0.86 ERCC1 (0.44) ERCC1ERCC4CARM1PRMT6SMO
SCHEMBL26418207 0.82 CARM1 (0.56) ERCC1ERCC4CARM1PRMT6SMO
SCHEMBL13103587 0.81 ERCC1 (0.54) ERCC1ERCC4CARM1PRMT6SMO
SCHEMBL26417663 0.78 ALOX15 (0.40) KMT2AALOX15ADRB2ADRA2ADRD2
SCHEMBL8310339 0.76 ERCC1 (0.56) ERCC1ERCC4SMOHPGDTSHR
SCHEMBL17662449 0.76 ELANE (0.40) KMT2AALOX15ADRB2ADRA2ADRD2
SCHEMBL26428984 0.75 ADRB2 (0.38) KMT2AALOX15TSHRADRB2ADRA2A
SCHEMBL14368078 0.75 ERCC1 (0.64) ERCC1ERCC4CARM1PRMT6SMO

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230128688-A1 DIRECTED CONJUGATION TECHNOLOGIES KLEO PHARMACEUTICALS, INC. 2023-04-27 US disclosed
US-20230128688-A1 DIRECTED CONJUGATION TECHNOLOGIES KLEO PHARMACEUTICALS, INC. 2023-04-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230128688-A1 DIRECTED CONJUGATION TECHNOLOGIES CD2BP2, CD2, CD47 ERCC1 3649/4885ERCC4 3737/4885CARM1 802/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.